Dyne Therapeutics, Inc. (DYN) Cash and securities
- Total cash · latest quarter (USD): Value $898.48M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $898.48M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $676.11M + $222.36M ≈ $898.48M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 676.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 222.36M USD | Debt Securities, Available-for-sale, Current |
| Cash and current securities | 898.48M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $898.48M | (m) | $676.11M | $222.36M | (m) |
| 2026-03-31 | $972.16M | (m) | $753.10M | $219.05M | (m) |
| 2025-12-31 | $1.11B | (m) | $893.37M | $217.19M | (m) |
| 2025-09-30 | $791.89M | (m) | $573.61M | $218.28M | (m) |
| 2025-06-30 | $683.92M | (m) | $485.04M | $198.88M | (m) |
| 2025-03-31 | $677.49M | (m) | $472.25M | $205.24M | (m) |
| 2024-12-31 | $642.27M | (m) | $435.45M | $206.82M | (m) |
| 2024-09-30 | $723.67M | (m) | $532.16M | $191.51M | (m) |
| 2024-06-30 | $778.84M | (m) | $608.20M | $170.64M | (m) |
| 2024-03-31 | $453.55M | (m) | $272.04M | $181.51M | (m) |
| 2023-12-31 | $123.10M | (m) | $121.63M | $1.47M | (m) |
| 2023-09-30 | $157.82M | (m) | $130.28M | $27.54M | (m) |
| 2023-06-30 | $207.73M | (m) | $167.61M | $40.13M | (m) |
| 2023-03-31 | $238.21M | (m) | $181.11M | $57.10M | (m) |
| 2022-12-31 | $256.01M | (m) | $172.15M | $83.86M | (m) |
| 2022-09-30 | $248.14M | (m) | $144.90M | $103.24M | (m) |
| 2022-06-30 | $291.84M | (m) | $135.98M | $155.86M | (m) |
| 2022-03-31 | $323.15M | (m) | $147.97M | $175.19M | (m) |
| 2021-12-31 | $376.57M | (m) | $200.82M | $175.75M | (m) |
| 2021-09-30 | $407.52M | (m) | $229.04M | $178.48M | (m) |
| 2021-06-30 | $435.59M | (m) | $258.38M | $177.20M | (m) |
| 2021-03-31 | $483.08M | (m) | $310.95M | $172.14M | (m) |
| 2020-12-31 | $345.31M | (m) | $300.85M | $44.46M | (m) |
| 2020-09-30 | (m) | (m) | $379.61M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $14.63M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |